Fall in Diffusing Capacity Associated With Induction Therapy for Lung Cancer: A Predictor of Postoperative Complication?
|
|
- Naomi James
- 5 years ago
- Views:
Transcription
1 SURGERY: The Annals of Thoracic Surgery CME Program is located online at To take the CME activity related to this article, you must have either an STS member or an individual non-member subscription to the journal. Fall in Diffusing Capacity Associated With Induction Therapy for Lung Cancer: A Predictor of Postoperative Complication? Shin-ichi Takeda MD, PhD, Yasunobu Funakoshi, MD, PhD, Yoshihisa Kadota, MD, PhD, Masaru Koma, MD, PhD, Hajime Maeda, MD, PhD, Satoko Kawamura, MD, and Yoko Matsubara, MD Departments of General Thoracic Surgery and Anesthesiology, Toneyama National Hospital, Toyonaka City, Osaka, Japan Background. Pulmonary resection after induction therapy is associated with high rates of pulmonary morbidity and mortality. However, the impact of induction therapy on the pulmonary toxicity and associated pulmonary complications has not been fully investigated in the setting of lung cancer surgery. Methods. We assessed the 66 consecutive patients who underwent a pulmonary resection after induction therapy, 48 of whom received chemoradiotherapy and 18, chemotherapy alone. Results of pulmonary function before and after induction therapy were compared, and logistic regression analyses utilized to explore the risk factors of pulmonary morbidity. Results. After induction therapy, forced expiratory volume in 1 second (FEV 1 ) was increased significantly (from L to L; p < 0.05); however, percent vital capacity (%VC) and FEV 1 /FVC did not change significantly. The diffusing capacity of lung for carbon monoxide (DLCO) was decreased significantly by 21% (from 90.3% 18.3% to 71.1% 12.5%; p < ). Patients with respiratory complication showed lower predicted postoperative %FEV 1 (49.5% 11.1% versus 57.2% 14.2%; p 0.031) and predicted postoperative %DLCO (41.9% 8.0% versus 55.4% 10.1%; p < ) results than those without complications. Univariate and multivariate analyses revealed that predicted postoperative %DLCO alone was an independent factor to predict postoperative pulmonary morbidity. Conclusions. For patients who undergo a pulmonary resection after induction therapy, predicted postoperative %DLCO is more important to predict pulmonary morbidity rather than static pulmonary function (predicted postoperative %VC or %FEV 1 ). The decrease in DLCO is thought to reflect a limited gas exchange reserve, caused by the potential toxicity of chemotherapy or chemoradiotherapy. We believe that the impact of diffusion limitation after induction therapy should to be emphasized to decrease the pulmonary morbidity. (Ann Thorac Surg 2006;82:232 6) 2006 by The Society of Thoracic Surgeons Recent applications of induction therapy have expanded the indications of surgery for locally advanced nonsmall-cell lung cancer (NSCLC) and improved postoperative survival. However, induction therapy has also been reported to increase the rates of operative morbidity and mortality [1 4], and a review our institutional experience revealed that the operative morality rate for patients who received a pulmonary resection after induction therapy was 5.5%, whereas it was 0.9% for patients who did not undergo induction therapy [5]. The study also showed that all patients who received induction therapy followed by surgery and then died of adult respiratory distress syndrome/acute lung injury Accepted for publication Jan 10, Address correspondence to Dr Takeda, Toneyama National Hospital, Toneyama 5-1-1, Toyonaka , Japan; stakeda@toneyama. hosp.go.jp. within 30 days had a normal pulmonary function except for a low level of lung diffusion for carbon monoxide (Dlco) [5]. Recently diverse experimental and clinical studies have shown that Dlco represents functional gas exchange capacity [6, 7], and can also independently predict the postoperative morbidity and mortality [8]. Further, Leo and colleagues [9] stressed that even though a reduction in Dlco is often subclinical, it can be a sensitive indicator of lung damage caused by chemotherapy and an important parameter for preoperative evaluation. Unlike patients with other malignancies such as breast and esophageal cancers, who may have lung damage due to the chemotherapy or radiation, lung cancer patients would suffer from further functional loss after undergoing a pulmonary resection. In the present study, we retrospectively reviewed our patient records to determine whether induction therapy 2006 by The Society of Thoracic Surgeons /06/$32.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg TAKEDA ET AL 2006;82:232 6 DIFFUSING CAPACITY AFTER INDUCTION THERAPY 233 Table 1. Pulmonary Function in 66 Patients Who Underwent Induction Therapy for Lung Cancer, and Compared Findings With Those of 200 Prethoracotomy Patients (Control) Control (n 200) has an effect on pulmonary function including lung volumes and Dlco values. In addition, we examined the relevance of impaired pulmonary function toward pulmonary morbidity. Patients and Methods Induction Therapy (n 66) p Value Male/female 138/62 52/ Age (years) Percent VC (%) FEV 1 (L) FEV 1 /FVC(%) Percent Dlco(%) a b a Dlco was corrected by hemoglobin value as described by Cotes et al [11]. b Statistically significant. Dlco diffusing capacity of lung for carbon monoxide; FEV 1 forced expiratory volume in 1 second; FVC forced vital capacity; VC vital capacity. Over a period of 10 years (1995 to 2005), pulmonary resections were performed for 911 consecutive patients with primary NSCLC at our hospital. Of those, 66 (51 males, 15 females; an average age of 60.0 years) who received induction therapy and were evaluated with full pulmonary function tests were included in the current study. Informed consent of induction therapy and preoperative pulmonary function test was obtained from all patients. The protocols of induction therapy were approved by the Institutional Review Board at our hospital. The histologic subtypes included 42 adenocarcinomas, 21 squamous cell carcinomas, and 3 large cell carcinomas. Clinical staging by the TNM classification [10] was performed as follows: evaluation of M1 disease included results from abdominal computed tomogram (CT), bone scan, brain CT, or magnetic resonance imaging (MRI) examinations as well as laboratory tests. There were 5 patients with c-iib disease (Pancoast type), 50 with c-iiia (n2), and 11 with c-iiib (8 patients with T4, invasion into the mediastinum or great vessels, and 3 patients with N3). In the early era, bulky N2 (c-iiia) were candidates for induction therapy without mediastinoscopy. Recently, we aggressively performed transbronchial needle aspiration cytology or mediastinoscopy, or both, for patients with clinical N2 disease before induction therapy. Forty-eight patients received chemoradiotherapy, and 18 underwent chemotherapy alone. Induction chemoradiotherapy consisted of more than two cycles of cisplatin/ vindesine/mitomycin-c or cisplatin/vindesine for 39 patients, and cisplatin/vinorelbine for 9 patients, with conventional radiation therapy applied with an average radiation of 42.5 Gy. Induction chemotherapy consisted of two cycles of cisplatin/vinorelbine for 4 patients, cisplatin/docetaxel for 4, and carboplatin/docetaxel for 10. The operative procedures included 46 lobectomies, 4 bilobectomies (including 8 sleeve resection), and 16 pneumonectomies, which included 63 R0 (no microscopically residual tumor) and 3 R1 (no gross residual tumors) resections. Two hundred consecutive lung cancer patients who underwent a pulmonary resection without induction therapy within the same period (1999 to 2001) were chosen and used as the control group to compare the pulmonary function values. The pulmonary function test and Dlco before and after induction therapy were determined in 32 patients, while those measurements were performed only after induction therapy (preoperation) in the other 34 patients. Spirometry was performed using a System 9 (Minato Medical Science, Osaka, Japan), and Dlco was measured by a single breath method and corrected with the hemoglobin value as reported by Cotes and associates [11]. Postoperative predictive pulmonary function including predicted postoperative percent vital capacity (ppo%vc), predicted postoperative percent FEV 1 (ppo%fev 1 ), and predicted postoperative percent Dlco (ppo%dlco) were estimated using lobar functional contribution as we previously reported [12], and a split function was applied using terchnetium-99mlabeled macroaggregates of albumin (99mTc-MAA) in case for pneumonectomy cases [13, 14]. The preinduction and postinduction therapy pulmonary function results were compared. To determine the predictors of postoperative morbidity, several factors including demographics, radiotherapy, preoperative and predictive pulmonary functional values were analyzed using logistic analysis. Postoperative pulmonary complications included pneumonia based on chest radiographic findings that required antibiotics, hypoxemia, atelectasis requiring repeated bronchofiberscopy, respiratory failure requiring reintubation with mechanical ventilation, and bronchopleural fistula, empyema, and severe chylothorax requiring reoperation. All other complication such as prolonged air leak, atrial fibrillation, and heart failure were not included in the analysis. Hospital mortality included 30-day mortality and operation-related deaths during the same hospitalization. Data are reported as the mean SD or as a proportion. Comparisons of pulmonary function measurements taken at preinduction and postinduction therapy were Table 2. Pulmonary Function Before and After Induction Therapy in 32 Patients Before After p Value Percent VC (%) FEV 1 (L) a FEV 1 /FVC(%) Percent Dlco(%) a a Statistically significant. Dlco diffusing capacity of lung for carbon monoxide; FEV 1 forced expiratory volume in 1 second; FVC forced vital capacity; VC vital capacity.
3 234 TAKEDA ET AL Ann Thorac Surg DIFFUSING CAPACITY AFTER INDUCTION THERAPY 2006;82:232 6 Table 3. Pulmonary Function and Complications in Patients Who Underwent Induction Therapy for Lung Cancer No Complications Complication (Death) p Value Number (5) Male/female 36/8 15/7 (4/1) Age (years) ( ) Percent VC (%) ( ) ppo%vc (%) ( ) FEV 1 (L) ( ) ppo%fev 1 (%) ( ) b FEV 1 /FVC(%) ( ) Percent Dlco(%) a ( ) b ppo%dlco(%) a ( ) b a Hemoglobin-adjusted Dlco. b Statistically significant. Dlco diffusing capacity of lung for carbon monoxide; FEV 1 forced expiratory volume in 1 second; FVC forced vital capacity; ppo predicted postoperative; VC vital capacity. performed using Student s paired t test. Comparisons were made using unpaired and 2 tests. To identify pulmonary function values, as well as clinical and demographic variables associated with pulmonary morbidity and mortality, stratified logistic regression analyses were subjected to explore the risk factors. Variables significantly related to the morbidity (p 0.1) in univariate analyses were considered in a multivariate analysis. Significance was accepted as a p value of less than 0.05 (StatView 5.0; Abacus Concepts, Berkeley, California). Results There were no significant differences in sex distribution, age, %VC, FEV 1, and FEV 1 /FVC values between the patients who underwent induction therapy and control group. In contrast, Dlco was lower in the induction therapy patients (p ) (Table 1). Further, an increase in FEV 1 was found after induction therapy (from L to L; p 0.05), however, and %VC and FEV 1 /FVC did not change significantly (Table 2). After being corrected by the hemoglobin value, Dlco was decreased significantly by 21% after induction therapy (from 90.3% 18.3% to71.1% 12.5%; p ). Operation-related deaths occurred in 5 patients (7.6%) including 2 with 30-day mortality (3.0%) due to adult respiratory distress syndrome and acute pulmonary embolism, and 3 late hospital deaths (empyema in 2 patients and respiratory failure in 1). Twenty-nine patients had postoperative complications (44.0%), and 22 patients (33.3%) experienced postoperative respiratory complications, which included 9 with pneumonia, 5 with respiratory failure requiring mechanical ventilation, 4, with atelectasis, 3 with empyema, and 3 with long-standing hypoxemia. Comparisons of predicted postoperative pulmonary function values between patients without complications (uncomplicated group, n 44) and those with complications (complication group, n 22) revealed no significant differences for sex distribution, age, preoperative %VC, ppo%vc, FEV 1, and FEV 1 /FVC (Table 2). In contrast, the complications group showed a lower ppo% FEV 1 (49.5% 11.1% versus 57.2% 14.2%; p 0.031), and significant differences were found for %Dlco (62.6% 9.7% versus 74.4% 11.5%; p ).and ppo%dlco (41.9% 8.0% versus 55.4% 10.1%; p ) (Table 3). Univariate and multivariate analyses (Table 4) revealed that ppo%dlco was a strong independent factor to predict postoperative pulmonary morbidity followed by ppo%vc (p ) and ppo%fev 1 (p ). In addition, ppo%dlco was the only independent factor able to predict pulmonary morbidity by multivariate analysis, while there were no predictors of postoperative mortality using similar analysis. Comment Induction therapy has shed a light for locally advanced NSCLC in terms of rendering them the tumors to be resectable [4, 15, 16]. However, a neutropenia and renal dysfunction as well as related susceptibility to infection have been reported in regards to patient eligibility in the setting of induction therapy [3, 15, 16]. In the present study, we focused on the change of lung volumes and diffusing capacity, and their relevance to pulmonary morbidity. In general, induction chemotherapy or chemoradiotherapy has favorable effects toward FEV 1 by ameliorating bronchial obstruction caused by tumor extension [17, 18], which was observed in the current patients. However, radiotherapy induced pulmonary toxicity toward Dlco has been reported [2, 4, 17 19] as well as that induced by the chemotherapeutic agents including bleomycin [19], mitomycin-c [20], gemcitabine [21], and cisplatin [21, 22]. Previous reports of high-dose chemotherapy for the treatment of nonseminomatous germ cell tumors showed that a 40% to 50% decrease in Dlco in patients who received high-dose chemotherapy [22 24], with operative deaths due to acute interstitial pneumonia or adult respiratory distress syndrome [24, 25]. In the current study, we did not clarify or compare the toxicity of each chemotherapeutic agent or the additive effects of radiation therapy. Nevertheless, our results showing a 14% to 20% decrease in Dlco by postoperative chemo-
4 Ann Thorac Surg TAKEDA ET AL 2006;82:232 6 DIFFUSING CAPACITY AFTER INDUCTION THERAPY 235 Table 4. Univariate Analysis of Factors Influencing the Pulmonary Morbidity and Mortality in 66 Patients After Induction Therapy Using Stepwise Logistic Regression Analysis Variable Subset Percent of PM RR (95% CI) p Value Age (years) 60 (n 38) ( ) (n 28) 35.7 Sex Male (n 51) ( ) Female (n 15) 33.3 Histology Sq La (n 24) ( ) Adenocarcinoma (n 42) 31.0 C stage T4 (n 11) ( ) T1 3 (n 55) 34.5 P stage IIIA, IIIB (n 20) ( ) I, II (n 46) 30.4 Radiation Yes (n 48) ( ) No (n 18) 27.8 Extended Yes (n 33) ( ) No (n 33) 30.3 ppo%vc (%) 70 (n 25) ( ) (n 41) 29.3 ppo%fev 1 (%) 50 (n 27) ( ) (n 39) 25.6 FEV 1 /FVC (%) 60 (n 15) ( ) (n 51) 31.4 ppo%dlco(%) a 40 (n 16) ( ) a 40 (n 50) 20 a Statistically significant. CI confidence interval; Dlco diffusing capacity of lung for carbon monoxide; FEV 1 forced expiratory volume in 1 second; FVC forced vital capacity; La large cell; PM pulmonary morbidity; RR relative risk; Sq squamous; VC vital capacity. therapy with carboplatin and paclitaxel (unpublished data) support the effects of chemotherapy alone. In addition to the effects of induction therapy and its pulmonary toxicity, further functional loss in the lung cancer patients due to a pulmonary resection is an important issue. Our finding thus clearly demonstrated the impact of chemotherapy and chemoradiotherapy on diffusing capacity and its relevance with respiratory complications after lung resections. In this sense, preoperative Dlco and ppo%dlco values were more important than lung volumes such as VC and FEV 1. Thus, the importance of diffusing limitation [8] was confirmed in the setting of induction therapy for NSCLC. Dissociation of lung volume and Dlco should not be overlooked when planning a lung resection for patients after induction therapy, particularly for those patients with marginal pulmonary functional reserve. It is known that diffusing capacity is composed of membranediffusing capacity (Dmco) and pulmonary capillary volume (Vc) [6, 7], and that Dlco increases with reference to the cardiac output. However, few studies have shown the effects of chemotherapeutic agents on Dmco and Vc, although bleomycin was found to decrease both components, while etoposide affected Dmco alone [25]. In our analysis of postoperative complications in patients who underwent induction therapy, major respiratory complications including radiation pneumonia, adult respiratory distress syndrome, and prolonged oxygen supplementation were frequently encountered. One explanation could be that those were associated with a decrease in Dlco as well as limited pulmonary vascular and lymphatic system reserves, which may have been due to pneumonitis induced by radiation or chemotherapy. The exclusive goal of induction therapy should be
5 236 TAKEDA ET AL Ann Thorac Surg DIFFUSING CAPACITY AFTER INDUCTION THERAPY 2006;82:232 6 exclusively aimed at complete surgical resection aiming at curing disease. Therefore, patients with marginal pulmonary function require additional functional evaluation in the light of their high-risk condition [4, 5]. Regarding such functional evaluation, we recently examined a method of exercise oxygen desaturation that represented diffusing limitation over the cardiac output [6, 8, 26, 27], with maximal oxygen uptake reflecting patient performance [13, 26] as an additional factor for making a final decision for lung resection candidates. Another aspect to consider regarding induction therapy is remote function after a lung resection. Previously, we analyzed the late pulmonary function in patients 1 year after undergoing a lobectomy, and found that that induction chemoradiotherapy alone was the factor that affected a postoperative decrease in VC and FEV 1 [28]. Those results in addition to the findings in current series reveal that a lung resection after induction therapy causes additional pulmonary function loss also in the late phase. Surgeons and anesthesiologists should consider the impact of induction therapy and impaired pulmonary function that occurs during the perioperative period. Further, low %Dlco strongly indicates subclinical lung damage and ppo%dlco can be used to predict the functional volume of gas exchange capacity [6 8]. The risks of surgery must be carefully balanced and individualized with a better chance for survival in locally advanced NSCLC patients requiring induction therapy as well as restaging after induction therapy to select the survival benefited patients and to avoid surgery for nonresponders. The authors wish to thank Dr Osamu Kuwahara, Dr Mitsunori Ohta, Dr Keiji Inada, Dr Noriyoshi Sawabata, Dr Masayoshi Inoue, Dr Shigeru Nakane, and Dr Masanobu Hayakawa, former attending thoracic surgeons, for their contributions to this project, and Yukari Hirai for her secretarial assistance. References 1. Fowler WC, Langer CJ, Curran WJ Jr, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993;55: Roberts JR, Eustis C, Devore R, Carbone D, Choy H, Johnson D. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 2001;72: Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancers. Ann Thorac Surg 2001;72: Stamatis G, Djuric D, Eberhardt W, et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients. Eur J Cardiothorac Surg 2002;22: Matsubara Y, Takeda S, Mashimo T. Risk stratification of lung cancer surgery: impact of induction therapy and extended surgery Chest 2005;128: Hsia CC. Recruitment of lung diffusing capacity: update concept and application.chest 2002;122: Takeda S, Wu EY, Epstein RH, Estrera AS, Hsia CC. In vivo assessment of changes in air and tissue volumes after pneumonectomy. J Appl Physiol 1997;82: Ferguson MK, Reeder LB, Mick R. Optimizing selection of patients for major lung resection. J Thorac Cardiovasc Surg 1995;109: Leo F, Solli P, Spaggiari L, et al. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 2004;77: Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111: Cotes JE, Dabbs JM, Elwood PC, et al. American Thoracic Society Board of Directors. Single-breath carbon monoxide diffusion capacity (transfer factor). Recommendation for a standard technique 1995 update. Am J Respir Crit Care Med 1995;152: Nakahara K, Monden Y, Ohno K, Miyoshi S, Maeda H, Kawashima Y. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer. Ann Thorac Surg 1985;39: Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989;139: Bria WF, Kanarek DJ, Kazemi H. Prediction of postoperative pulmonary function following thoracic operations: value of ventilation-perfusion scanning. J Thorac Cardiovasc Surg 1983;86: Sugarbaker DJ, Herndon J, Kohman LJ, and the Cancer and Leukemia Group B Thoracic Surgery Group. Results of cancer and leukemia group B protocol A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg 1995;109: Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB. J Clin Oncol 1995;13: Miller KL, Zhou SM, Barrier RC Jr, et al. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2003;56: Gopal R, Starkschall G, Tucker SL, et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56: Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin s disease on pulmonary function. Results of a prospective study. J Clin Oncol 1994; 12: Castro M, Veeder MH, Mailliard JA, Tazelaar HD, Jett JR. A prospective study of pulmonary function in patients receiving mitomycin. Chest 1996;109: Maas KW, van der Lee I, Bolt K, Zanen P, Lammers JW, Schramel FM. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 2003;41: Bhalla KS, Wilczynski SW, Abushamaa AM, et al.pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000;161: Takeda S, Miyoshi S, Ohta M, Minami M, Masaoka A, Matsuda H. Primary germ cell tumors in the mediastinum. A 50 year experience at a single Japanese institution. Cancer 2003;97: Andrade RS, Kesler KA, Wilson JL, et al. Short-and long term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy. Ann Thorac Surg 2004;78: Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Decrease in pulmonary function during bleomycincontaining combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995;71: Pate P, Tenholder MF, Griffin JP, Eastridge CE, Weiman DS. Preoperative assessment of the high risk patient for lung resection. Ann Thorac Surg 1996;61: Filaire M, Bedu M, Naamee A, et al. Prediction of hypoxemia and mechanical ventilation after resection for cancer. Ann Thorac Surg 1999;67: Funakoshi Y, Takeda S, Sawabata N, Okumura Y, Maeda H. Long term pulmonary function after lobectomy for primary lung cancer. Asian Cardiovasc Thorac Ann 2005;13:311 8.
The right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationPrapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital
Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled
More informationDoes chemotherapy increase the risk of respiratory complications after pneumonectomy?
Does chemotherapy increase the risk of respiratory complications after pneumonectomy? Francesco Leo, MD, a PierGiorgio Solli, MD, a Giulia Veronesi, MD, a Davide Radice, PhD, b Antonio Floridi, MD, a Roberto
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationModeling major lung resection outcomes using classification trees and multiple imputation techniques
European Journal of Cardio-thoracic Surgery 34 (2008) 1085 1089 www.elsevier.com/locate/ejcts Modeling major lung resection outcomes using classification trees and multiple imputation techniques Mark K.
More informationLung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationParenchymal air leak is a frequent complication after. Pleural Tent After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect
Pleural After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect Alessandro Brunelli, MD, Majed Al Refai, MD, Marco Monteverde, MD, Alessandro Borri, MD, Michele Salati, MD, Armando
More informationInduction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor
Original Article Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor Katsuhiko Shimizu, 1 Masao Nakata, 1 Ai Maeda, 1 Takuro Yukawa,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationPostoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationImpact of limited pulmonary function on the management of resectable lung cancer
Lung Cancer (2003) 41, 71/79 www.elsevier.com/locate/lungcan Impact of limited pulmonary function on the management of resectable lung cancer Piergiorgio Solli a, *,1, Francesco Leo a, Giulia Veronesi
More informationCytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer
Cytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer Noriyoshi Sawabata, MD, Akihide Matsumura, MD, Mitsunori Ohota, MD, Hajime Maeda, MD, Hiroshi Hirano, MD, Katsuhiro
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationDifferent Diffusing Capacity of the Lung for Carbon Monoxide as Predictors of Respiratory Morbidity
Different Diffusing Capacity of the Lung for Carbon Monoxide as Predictors of Respiratory Morbidity Robert J. Cerfolio, MD, and Ayesha S. Bryant, MSPH, MD Department of Surgery, Division of Cardiothoracic
More informationDespite recent advances in the treatment of non-small cell
ORIGINAL ARTICLE Contemporary Results of Surgical Resection of Non-small Cell Lung Cancer After Induction Therapy A Review of 549 Consecutive Cases Stephen A. Barnett, MBBS,* Valerie W. Rusch, MD,* Junting
More informationEarly-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Pieter Postmus The Clatterbridge Cancer Centre Liverpool Heart and Chest Hospital Liverpool, United Kingdom 1 2
More informationPreoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection
Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant, MD, Sonia Blandin, MD, Isabelle Arnaud, MD, Pascal
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationFariba Rezaeetalab Associate Professor,Pulmonologist
Fariba Rezaeetalab Associate Professor,Pulmonologist rezaitalabf@mums.ac.ir Patient related risk factors Procedure related risk factors Preoperative risk assessment Risk reduction strategies Age Obesity
More informationThe cardiopulmonary exercise test (CPET) has been
Minute Ventilation-to-Carbon Dioxide Output (V E/V CO2 ) Slope Is the Strongest Predictor of Respiratory Complications and Death After Pulmonary Resection Alessandro Brunelli, MD, Romualdo Belardinelli,
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationPredicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection*
Predicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection* Bernhardt G. Zeiher, MD; Thomas ]. Gross, MD; Jeffery A. Kern, MD, FCCP; Louis A. Lanza, MD, FCCP; and Michael W. Peterson,
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationSleeve Lobectomy Compared with Pneumonectomy after Induction Therapy for Non Small-Cell Lung Cancer
Original Article Sleeve Lobectomy Compared with Pneumonectomy after Induction Therapy for Non Small-Cell Lung Cancer Giulio Maurizi, MD,* Antonio D Andrilli, MD,* Marco Anile, MD, Anna Maria Ciccone, MD,*
More informationModerate abnormality of gas exchange frequently
Prediction of Hypoxemia and Mechanical Ventilation After Lung Resection for Cancer Marc Filaire, MD, Mario Bedu, MD, Adel Naamee, MD, Sylvie Aubreton, PhT, Laurent Vallet, MD, Bernadette Normand, PhD,
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationLung cancer is generally a disease of older adults, and
B-Type Natriuretic Peptide as a Predictor of Postoperative Cardiopulmonary in Elderly Patients Undergoing Pulmonary Resection for Lung Cancer Takashi Nojiri, MD, Masayoshi Inoue, MD, PhD, Kazuhiro Yamamoto,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationDoes preoperative predictive lung functions correlates with post surgical lung functions in lobectomy?
Preoperative and post surgical lung functions in lobectomy Original Research Article ISSN: 2394-0026 (P) Does preoperative predictive lung functions correlates with post surgical lung functions in lobectomy?
More informationThoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae
More informationShort-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
More informationPOINT: Operative risk of pneumonectomy Influence of preoperative induction therapy
Gaissert et al Point/Counterpoint POINT: Operative risk of pneumonectomy Influence of preoperative induction therapy Henning A. Gaissert, MD, Dong Yoon Keum, MD, Cameron D. Wright, MD, Marek Ancukiewicz,
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationSubpleural Honeycombing on High Resolution Computed Tomography is Risk Factor for Fatal Pneumonitis
Subpleural Honeycombing on High Resolution Computed Tomography is Risk Factor for Fatal Pneumonitis Hiroyuki Ito, MD, Haruhiko Nakayama, MD, Masahiro Tsuboi, MD, MD, Yoichi Kameda, MD, Tomoyuki Yokose,
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationTrimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
Aravot et al. Journal of Cardiothoracic Surgery (2019) 14:7 https://doi.org/10.1186/s13019-018-0829-z RESEARCH ARTICLE Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationYutian Lai #, Xin Wang #, Pengfei Li, Jue Li, Kun Zhou, Guowei Che. Introduction
Original Article Preoperative peak expiratory flow (PEF) for predicting postoperative pulmonary complications after lung cancer lobectomy: a prospective study with 725 cases Yutian Lai #, Xin Wang #, Pengfei
More informationAkihiro Hayashi, MD, Shinzo Takamori, MD, Masahiro Mitsuoka, MD, Keisuke Miwa, MD, Mari Fukunaga, MD, Keiko Matono, MD, and Kazuo Shirouzu, MD
Case Report The UPAO Test in Preoperative Evaluation for Major Pulmonary Resection: An Operative Case with Markedly Improved Ventilatory Function after Radical Pulmonary Resection for Lung Cancer Associated
More informationThe T4 category of lung cancer is defined by invasion of the
Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationPreoperative risk assessment with computed tomography in patients undergoing lung cancer surgery
Original Article Preoperative risk assessment with computed tomography in patients undergoing lung cancer surgery Kazuhiro Ueda, Junichi Murakami, Toshiki Tanaka, Masataro Hayashi, Kazunori Okabe, Kimikazu
More informationIdiopathic pulmonary fibrosis (IPF), also referred to as
Operation for Lung Cancer in Patients With Idiopathic Pulmonary Fibrosis: Surgical Contraindication? Toshio Fujimoto, MD, Tsuyoshi Okazaki, MD, Tadashi Matsukura, MD, Takeshi Hanawa, MD, Naoki Yamashita,
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationTumors of the superior sulcus and central T4 tumors are an
ORIGINAL ARTICLE Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD,* Johan Vansteenkiste, MD, PhD, Yolande Lievens, MD, PhD, Dirk
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationLung resection still achieves the best long-term results
Quality of Life Before and After Major Lung Resection for Lung Cancer: A Prospective Follow-Up Analysis Alessandro Brunelli, MD, Laura Socci, MD, Majed Refai, MD, Michele Salati, MD, Francesco Xiumé, MD,
More informationWine cup stoma anastomosis after extended sleeve lobectomy for central-type squamous cell lung cancer
Higuchi et al. Journal of Cardiothoracic Surgery (2019) 14:36 https://doi.org/10.1186/s13019-019-0857-3 CASE REPORT Open Access Wine cup stoma anastomosis after extended sleeve lobectomy for central-type
More informationRadiotherapy for Locoregional Recurrent Non-Small Cell Lung Cancer
J Lung Cancer 2011;10(1):37-43 Radiotherapy for Locoregional Recurrent Non-Small Cell Lung Cancer Purpose: To retrospectively evaluate the outcomes and complications of curative radiotherapy for locoregionally
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationLung cancer is the leading cause of cancer-related
Advanced Non-Small Cell Lung Cancer: Induction Chemotherapy and Chemoradiation Before Operation Arnold Cyjon, MD, Moshe Nili, MD, Gershon Fink, MD, Mordechai R. Kramer, MD, Eyal Fenig, MD, Judith Sandbank,
More informationImpact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer
Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationD tion therapy, complete resection of a tumor offers
Determinants of Perioperative Morbidity and Mortality After Pneumonectomy Rakesh Wahi, MBBS, Marion J. McMurtrey, MD, Louis F. DeCaro, MD, Clifton F. Mountain, MD, Mohamed K. Ali, MD, Terry L. Smith, MS,
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationPLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.
Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form RTOG Study No. 0813 Case # Name RTOG Patient ID INSTRUCTIONS: Submit this form at the appropriate followup
More informationAdvanced Lung Cancer Inflammation Index Predicts Outcomes of Patients with Pathological Stage IA Lung Adenocarcinoma Following Surgical Resection
doi: 10.5761/atcs.oa.18-00158 Original Article Advanced Lung Cancer Inflammation Index Predicts Outcomes of Patients with Pathological Stage IA Lung Adenocarcinoma Following Surgical Resection Satoru Kobayashi,
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Can We Make Pneumonectomy Great Again? Kenneth A. Kesler, MD PII: S0022-5223(18)31793-8 DOI: 10.1016/j.jtcvs.2018.06.048 Reference: YMTC 13173 To appear in: The Journal of Thoracic
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationCarcinoma of the esophagus continues to carry a
Pulmonary Complications After Esophagectomy Christopher E. Avendano, MD, Patrick A. Flume, MD, Gerard A. Silvestri, MD, Lydia B. King, MPH, and Carolyn E. Reed, MD Departments of Medicine, Biometry and
More informationPersistent Cough Following Pulmonary Resection: Observational and Empiric Study of Possible Causes
Persistent Cough Following Pulmonary : Observational and Empiric Study of Possible Causes Noriyoshi Sawabata, MD, Hajime Maeda, MD, Shin-ichi Takeda, MD, Masayoshi Inoue, MD, Masaru Koma, MD, Toshiteru
More informationDLCO and postpneumonectomy complications RELATIONSHIP OF CARBON MONOXIDE PULMONARY DIFFUSING CAPACITY TO POSTOPERATIVE CARDIOPULMONARY COMPLICATIONS I
RELATIONSHIP OF CARBON MONOXIDE PULMONARY DIFFUSING CAPACITY TO POSTOPERATIVE CARDIOPULMONARY COMPLICATIONS IN PATIENTS UNDERGOING PNEUMONECTOMY Jeng-Shing Wang Respiratory Medicine Section, Vancouver
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationLung cancer is the leading cause of cancer-related death in
ORIGINAL ARTICLE Preoperative Exercise VO 2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238 Gregory M. Loewen, DO,* Dorothy Watson, MS, Leslie Kohman, MD,
More informationChapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension
Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir
More informationCHAPTER 5 TUMOR SIZE DOES NOT PREDICT PATHOLOGICAL COMPLETE RESPONSE RATES AFTER PRE-OPERATIVE CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER
TUMOR SIZE DOES NOT PREDICT PATHOLOGICAL COMPLETE RESPONSE RATES AFTER PRE-OPERATIVE CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER Cornelis G. Vos Max R. Dahele Chris Dickhoff Suresh Senan Erik Thunnissen
More informationNon small-cell lung cancers (NSCLCs) located along
Original Article Long-Term Outcome after En Bloc Resection of Non Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc,* Thomas K. Waddell, MD, PhD,* Kazuhiro Yasufuku,
More informationThe effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University Disclosures I have no conflict of interest disclosures
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationSurgical and survival outcomes of lung cancer patients with intratumoral lung abscesses
Yamanashi et al. Journal of Cardiothoracic Surgery (2017) 12:44 DOI 10.1186/s13019-017-0607-3 RESEARCH ARTICLE Open Access Surgical and survival outcomes of lung cancer patients with intratumoral lung
More informationConcurrent chemoradiotherapy (CCRT) is considered
ORIGINAL ARTICLE Tumor Cavitation in Patients With Stage III Non Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy Incidence and Outcomes Erik C. J. Phernambucq, MD,* Koen J. Hartemink, MD,
More informationTHE MAJORITY of patients with locally advanced lung
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pn2 Non Small-Cell Lung Cancer: A Multicenter Phase II Trial Daniel
More information